PMID- 25408787
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141121
LR  - 20181113
IS  - 0011-393X (Print)
IS  - 1879-0313 (Electronic)
IS  - 0011-393X (Linking)
VI  - 76
DP  - 2014 Dec
TI  - Low concentration of rapamycin inhibits hemangioma endothelial cell 
      proliferation, migration, and vascular tumor formation in mice.
PG  - 99-103
LID - 10.1016/j.curtheres.2014.09.004 [doi]
AB  - BACKGROUND: Vascular endothelial cell excessive proliferation is the main 
      biological behavior of hemangioma. Rapamycin regulates the growth of endothelial 
      cells by inhibiting mammalian target of rapamycin (mTOR). Thus hemangioma 
      accompanied by excessive mTOR activation should be sensitive to rapamycin. We 
      aimed to illustrate the effect of low-concentration rapamycin on hemangioma and 
      provide a safe and effective drug therapy. METHODS: Mouse hemangioendothelioma 
      endothelial cells and Nu/Nu mice were used. Rapamycin was applied in a 
      concentration from 1 nM to 20 nM. WST-1 cell proliferation and transwell 
      migration assays were used to analyze vascular tumor proliferation and migration 
      in vitro. Xenograft mouse models were used to test vascular tumor growth in vivo. 
      RESULTS: Low-concentration rapamycin (1 nM) inhibited hemangioendothelioma 
      endothelial cell proliferation and migration in vitro and vascular tumor growth 
      in vivo. The mechanism was decreased activation of the protein kinase B/mTOR/S6 
      ribosomal protein (S6) signaling pathway. CONCLUSIONS: Rapamycin used in vitro 
      was analogous to low serum concentration rapamycin (7-16 nM) and also 
      significantly inhibited the growth of hemangioma. These results demonstrate a 
      low-toxic drug therapy for hemangioma and encourage continued development of 
      rapamycin and its analogs for use in vascular tumor therapy.
FAU - Zheng, Ningning
AU  - Zheng N
AD  - Department of Pathophysiology, China Medical University, Shenyang, China.
FAU - Ding, Xudong
AU  - Ding X
AD  - Department of Anesthesiology, Shengjing Hospital of China Medical University, 
      Shenyang, China.
FAU - Jahan, Rabita
AU  - Jahan R
AD  - International Education School, China Medical University, Shenyang, China.
LA  - eng
PT  - Journal Article
DEP - 20141111
PL  - United States
TA  - Curr Ther Res Clin Exp
JT  - Current therapeutic research, clinical and experimental
JID - 0372621
PMC - PMC4229512
OTO - NOTNLM
OT  - Hemangioma
OT  - mechanistic target of rapamycin
OT  - protein kinase B
OT  - rapamycin
EDAT- 2014/11/20 06:00
MHDA- 2014/11/20 06:01
PMCR- 2014/11/11
CRDT- 2014/11/20 06:00
PHST- 2014/09/16 00:00 [accepted]
PHST- 2014/11/20 06:00 [entrez]
PHST- 2014/11/20 06:00 [pubmed]
PHST- 2014/11/20 06:01 [medline]
PHST- 2014/11/11 00:00 [pmc-release]
AID - S0011-393X(14)00024-1 [pii]
AID - 10.1016/j.curtheres.2014.09.004 [doi]
PST - epublish
SO  - Curr Ther Res Clin Exp. 2014 Nov 11;76:99-103. doi: 
      10.1016/j.curtheres.2014.09.004. eCollection 2014 Dec.